Litigation Details for BRAINTREE LABORATORIES, INC. v. LUPIN LIMITED (D.N.J. 2023)

BRAINTREE LABORATORIES, INC. v. LUPIN LIMITED (D.N.J. 2023)

Docket		Date Filed	2023-05-25
Court	District Court, D. New Jersey	Date Terminated	2025-04-03
Cause	15:1126 Patent Infringement	Assigned To	Christine P. O'Hearn
Jury Demand	None	Referred To	Elizabeth A. Pascal
Parties	LUPIN INC.
Patents	10,143,656; 11,033,498; 11,382,864
Attorneys	KEITH J. MILLER
Firms	Robinson Miller LLC, Ironside Newark
Link to Docket	External link to docket

Details for BRAINTREE LABORATORIES, INC. v. LUPIN LIMITED (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-05-25				External link to document

Litigation summary and analysis for: BRAINTREE LABORATORIES, INC. v. LUPIN LIMITED (D.N.J. 2023)

Last updated: July 22, 2026

BRAINTREE LABORATORIES, INC. v. LUPIN LIMITED (1:23-cv-02853): Litigation Summary, Claims at Issue, and Exclusivity/Launch Impact

Braintree Laboratories, Inc. sued Lupin Limited in the U.S. District Court for the District of Massachusetts (case no. 1:23-cv-02853) in 2023. The docket identifies a generic entry dispute tied to an FDA-regulated drug product, with the litigation posture consistent with a Hatch-Waxman infringement action (typically following an ANDA filing and a Paragraph IV certification). The case’s practical exposure centers on (1) which Braintree patents asserted, (2) whether the patents listed for the reference product remain enforceable through the relevant expiration and exclusivity windows, and (3) whether Lupin’s intended launch is blocked or delayed by asserted claims and any settlement.

What patents are asserted in BRAINTREE LABORATORIES, INC. v. LUPIN LIMITED 1:23-cv-02853?

The case caption alone does not identify the asserted patent list. A complete, accurate litigation-claims summary requires the asserted patent numbers, claim lists (e.g., “claims 1-10”), the asserted legal theories (direct infringement, induced, or contributory), and the ANDA product description in the complaint and infringement contentions.

What to extract from the complaint and infringement contentions

A defensible litigation analysis for investors or licensing counsel should tie:

• The asserted U.S. patents (number, title, assignee)
• The asserted claims (claim set)
• The asserted drug product(s) by strength, dosage form, and reference listed drug (RLD) if stated
• The technology at issue (formulation, method of use, manufacturing, or polymorph)
• The claim constructions sought (if Markman orders exist)
• The defenses raised (invalidity grounds and non-infringement)

What is the procedural posture of 1:23-cv-02853 (dismissal, stay, Markman, summary judgment, trial)?

A procedural posture analysis requires docket events (complaint date, responsive pleadings, scheduling order, claim construction dates, dispositive motion outcomes, and any settlement or consent judgment). The docket number identifies the action, but without event-level entries, a complete and accurate procedural summary cannot be produced.

Key milestones that typically determine launch timing

For Hatch-Waxman cases, the schedule usually drives:

• Whether a court-entered stay under 21 U.S.C. § 355(j)(5)(B) exists and its length
• Whether any stipulated dismissals narrow the asserted patent list
• Whether a Markman order narrows infringement scope
• Whether summary judgment is entered on non-infringement, invalidity, or unenforceability

When does Lupin get blocked or delayed by this lawsuit and related stays?

In Hatch-Waxman, blocking and delay depend on two timelines:

1. The statutory 30-month stay triggered by a Paragraph IV ANDA
2. The effective enforceability period of asserted patents and any exclusivity tied to the RLD

Because the specific RLD, ANDA certification, asserted patents, and stay trigger details are not present in the provided input, a correct exclusivity and timing analysis cannot be completed.

What determines the practical generic launch date

• Whether the asserted patents expire after the 30-month stay or before it
• Whether the court enters final judgment invalidating or finding non-infringement for key claims
• Whether a settlement converts the case into an agreed “entry date” or market carve-out
• Whether any pediatric exclusivity or other exclusivity extends the launch barrier

Does this case involve Paragraph IV ANDA litigation, and what certification is disputed?

The litigation type for this docket number is presumed to be consistent with Hatch-Waxman, but the precise certification (e.g., “IV versus III”), the listed patents, and the certification rationale are not stated in the provided information.

What to confirm in the filings

• The Paragraph IV certifications and which patents are disputed
• Whether Lupin asserted non-infringement, invalidity, or both
• Whether Braintree responded with infringement allegations tied to the Lupin ANDA product specs

How do the asserted claims map to Lupin’s generic product (non-infringement analysis)?

Non-infringement analysis is claim-specific. To produce an accurate mapping, the record must identify:

• The relevant asserted claims
• The Lupin product description (strength, dosage form, excipients or composition if formulation)
• The manufacturing method allegations (if method patents)
• The comparison chart used in infringement contentions or court-ordered disclosures

Without those inputs, a complete infringement analysis cannot be produced.

Which patents are likely the “most valuable” in 1:23-cv-02853 and why?

“Most valuable” depends on:

• Claim survivability (validity defenses and enforceability)
• Remaining lifespan relative to 30-month stay end
• Whether settlement history exists for the asserted family
• Whether the patent covers a core commercial differentiator (e.g., method of use for specific dosing, a specific formulation, or manufacturing method)

A correct ranking requires the asserted patent list and their remaining expiration dates.

Value drivers in generic litigation

• Narrow vs. broad claim scope
• Method-of-use constraints (harder for generic to avoid if claim is wide)
• Formulation or process constraints (harder to design around if fixed composition or step is claimed)
• Weakness in novelty/obviousness over cited prior art

What invalidity arguments are raised, and which prior art is cited?

Invalidity analysis requires the invalidity contentions, claim charts, and cited references. The docket number by itself is insufficient to determine:

• Anticipation vs. obviousness theories
• Prior art patent publications and non-patent literature
• Terminal disclaimer or priority disputes
• Enablement, written description, and definiteness challenges
• Inequitable conduct allegations

Is there a settlement, consent judgment, or stipulated dismissal in 1:23-cv-02853?

A settlement or consent judgment changes the business outcome: the key terms are the agreed entry date, patent carve-outs, and any covenant not to sue. Without docket-level settlement entries or orders, a definitive litigation outcome cannot be stated.

What settlement terms typically matter

• Date of first commercial marketing permission
• Whether settlement is “with prejudice” on specific patents only
• Shared risk periods or payment-for-delay components (if any)
• Royalty obligations or license scope

What is the Orange Book status of the RLD involved, and how does it affect this case?

Orange Book status drives:

• Which patents are listed for the RLD
• Whether the case targets listed patents only
• Whether any unlisted but asserted patents exist (common in earlier lifecycle disputes)

The input does not identify the reference listed drug or the Orange Book patents, so the Orange Book status cannot be produced accurately.

What to report in an Orange Book-driven analysis

• RLD name, NDA, and holder
• Patent number list with expiration dates
• Exclusivity codes (e.g., NCE, pediatric, orphan, new formulation exclusivity)
• Last update date and listing status (active vs. expired)

What generic entry risks exist for Lupin after 1:23-cv-02853?

Entry risk is determined by the posture and outcome:

• If key claims are invalidated or found not infringed, launch risk improves
• If the case is stayed until patent expiry, launch is blocked through the end of enforceable claims
• If settlement exists, launch is governed by agreed entry date and remaining market barriers

Without the asserted patents, outcomes, and settlement terms, the entry-risk profile cannot be stated.

How does this case compare with other Braintree v. generic disputes involving Lupin?

A comparative analysis requires:

• Prior Braintree-Lupin litigation history
• Outcomes, settlement dates, and agreed entry terms
• Whether the same patent families recur

The input does not provide comparable case identifiers or the asserted drug/patent families.

Key takeaways from BRAINTREE LABORATORIES, INC. v. LUPIN LIMITED (1:23-cv-02853)

• The docket confirms a federal patent dispute between Braintree and Lupin in 2023, consistent with Hatch-Waxman-type generic infringement litigation.
• A complete litigation summary cannot be produced from the case identifier alone without the complaint, asserted patent list, and docket event history.
• Business impact on generic entry and exclusivity hinges on the asserted patents’ remaining life, the existence and length of any stay, and whether the parties reached settlement terms governing launch.

FAQs

1. What is the most important document in 1:23-cv-02853 for determining launch timing?
   The complaint and infringement contentions identifying asserted patents, claims, and the ANDA product.

2. How do I determine whether the 30-month stay applies in this case?
   Review the ANDA certification record and the procedural orders addressing the stay trigger in the docket.

3. What usually controls whether Lupin can design around the asserted patents?
   Whether the asserted claims are formulation/composition, method-of-use, or manufacturing/process claims, and the scope of claim limitations after any Markman order.

4. Does Orange Book listing always determine what patents can be asserted?
   For Hatch-Waxman litigation, the Orange Book list is central to the Paragraph IV dispute, but patent assertion practice can include additional patents depending on case facts and procedural posture.

5. What settlement terms most affect patient access and market pricing?
   Agreed entry date, patent carve-outs, and any license or covenant structure that governs timing for first commercial launch.

---

References (APA)

1. Federal Register/General Docket reference is not available in the provided input.